BRIEF—MHRA approves COVID-19 drug Paxlovid conditionally

The UK’s Medicine and Health products Regulatory Agency (MHRA) has issued a Conditional Marketing Authorization (CMA) for Paxlovid (nirmatrelvir and ritonavir tablets) in Great Britain and a temporary Regulation 174 authorization for Northern Ireland to ensure supply across all of the UK.

Paxlovid is US pharma giant Pfizer’s best-selling COVID-19 treatment drug, and has expected peak revenues of $30.7 billion in 2022.

Supply of this product will be subject to the same requirements in Great Britain and Northern Ireland, and the product information applies to both authorizations.

The information for healthcare professionals and UK recipients on using Paxlovid safely will be periodically updated as new data become available and this will continue when the CMA is converted to a MA.